These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 31620934)

  • 81. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
    Liu D
    Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
    [TBL] [Abstract][Full Text] [Related]  

  • 82. BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.
    Kwon MJ; Lee SB; Han J; Lee JE; Lee JW; Gong G; Beitsch PD; Nam SJ; Ahn SH; Nam BH; Shin YK
    PLoS One; 2018; 13(11):e0207155. PubMed ID: 30462685
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy.
    Yoon TI; Hwang UK; Kim ET; Lee S; Sohn G; Ko BS; Lee JW; Son BH; Kim S; Ahn SH; Kim HJ
    Breast Cancer Res Treat; 2017 Sep; 165(2):311-320. PubMed ID: 28601930
    [TBL] [Abstract][Full Text] [Related]  

  • 84. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.
    Lei J; Rudolph A; Moysich KB; Rafiq S; Behrens S; Goode EL; Pharoah PP; Seibold P; Fasching PA; Andrulis IL; Kristensen VN; Couch FJ; Hamann U; Hooning MJ; Nevanlinna H; Eilber U; Bolla MK; Dennis J; Wang Q; Lindblom A; Mannermaa A; Lambrechts D; García-Closas M; Hall P; Chenevix-Trench G; Shah M; Luben R; Haeberle L; Ekici AB; Beckmann MW; Knight JA; Glendon G; Tchatchou S; Alnæs GI; Borresen-Dale AL; Nord S; Olson JE; Hallberg E; Vachon C; Torres D; Ulmer HU; Rüdiger T; Jager A; van Deurzen CH; Tilanus-Linthorst MM; Muranen TA; Aittomäki K; Blomqvist C; Margolin S; Kosma VM; Hartikainen JM; Kataja V; Hatse S; Wildiers H; Smeets A; Figueroa J; Chanock SJ; Lissowska J; Li J; Humphreys K; Phillips KA; ; Linn S; Cornelissen S; van den Broek SA; Kang D; Choi JY; Park SK; Yoo KY; Hsiung CN; Wu PE; Hou MF; Shen CY; Teo SH; Taib NA; Yip CH; Ho GF; Matsuo K; Ito H; Iwata H; Tajima K; Dunning AM; Benitez J; Czene K; Sucheston LE; Maishman T; Tapper WJ; Eccles D; Easton DF; Schmidt MK; Chang-Claude J
    Breast Cancer Res; 2015 Feb; 17(1):18. PubMed ID: 25849327
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Clinicopathological Features and Long-Term Prognostic Role of Human Epidermal Growth Factor Receptor-2 Low Expression in Chinese Patients with Early Breast Cancer: A Single-Institution Study.
    Kong ZQ; Liu LQ; Huang Q; Wang YT; Li JJ; Zhang Z; Wang XX; Liu CL; Zhang YD; Shao JK; Zhu YM; Chen YM; Liu M; Zhao WH
    Biomed Environ Sci; 2024 May; 37(5):457-470. PubMed ID: 38843919
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.
    Lee HJ; Park IA; Park SY; Seo AN; Lim B; Chai Y; Song IH; Kim NE; Kim JY; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2014 Jun; 145(3):615-23. PubMed ID: 24820412
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients.
    Jin X; Jiang YZ; Chen S; Shao ZM; Di GH
    Sci Rep; 2016 Aug; 6():32585. PubMed ID: 27576704
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
    Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A Nomogram for Predicting Liver Metastasis of Lymph-Node Positive Luminal B HER2 Negative Subtype Breast Cancer by Analyzing the Clinicopathological Characteristics of Patients with Breast Cancer.
    Yue Y; Liang J; Wu Y; Tong W; Li D; Cao X; Wang X
    Technol Cancer Res Treat; 2022; 21():15330338221132669. PubMed ID: 36254567
    [No Abstract]   [Full Text] [Related]  

  • 92. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients.
    Wu J; Gao W; Chen X; Fei C; Lin L; Chen W; Huang O; Zhu S; He J; Li Y; Zhu L; Shen K
    Front Med; 2021 Aug; 15(4):621-628. PubMed ID: 33367943
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
    Aljohani AI; Joseph C; Kurozumi S; Mohammed OJ; Miligy IM; Green AR; Rakha EA
    Breast Cancer Res Treat; 2020 Jun; 181(3):541-551. PubMed ID: 32350677
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Select gene mutations associated with survival outcomes in ER-positive ERBB2-negative early-stage invasive breast cancer: A single-institutional tissue bank study.
    Kok VC; Huang TY; Hsu YC; Chang YC; Yang PS
    Cancer Med; 2024 Jul; 13(14):e70035. PubMed ID: 39031010
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Integrated analysis of cell cycle-related genes in HR+/HER2- breast cancer.
    Lai J; Chen B; Li Y; Lin X; Li M; Liu J; Liao N
    Breast Cancer; 2022 Jan; 29(1):121-130. PubMed ID: 34449047
    [TBL] [Abstract][Full Text] [Related]  

  • 98. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
    Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
    Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Tumor subtypes and survival in male breast cancer.
    Leone J; Freedman RA; Lin NU; Tolaney SM; Vallejo CT; Leone BA; Winer EP; Leone JP
    Breast Cancer Res Treat; 2021 Aug; 188(3):695-702. PubMed ID: 33770314
    [TBL] [Abstract][Full Text] [Related]  

  • 100. FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
    Mouron S; Manso L; Caleiras E; Rodriguez-Peralto JL; Rueda OM; Caldas C; Colomer R; Quintela-Fandino M; Bueno MJ
    Breast Cancer Res; 2021 Feb; 23(1):21. PubMed ID: 33579347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.